Lucy Cavendish says she is among the first women in Britain to take the weight-loss pill Wegovy. In her account, she describes receiving a small, white, turquoise-coloured delivery box last week and reacting positively when it arrived. She characterizes the early stage of treatment as “early days,” adding that the experience is already “very different to the jabs,” which she refers to as earlier injection-based weight-loss approaches. The reports focus on her personal experience rather than providing detailed medical results, dosing information, side effects, or independent evidence. Both outlets present the same narrative: that Wegovy is now accessible to a limited number of people in the UK and that Cavendish is trying it during an initial period after delivery. The coverage does not include outcomes such as weight loss figures or clinical assessments, and it does not outline broader availability or prescribing criteria beyond the suggestion that uptake is limited among early users.